PDS Biotechnology announces updates data from VERSATILE-002 trial - TipRanks.com
PDS Biotechnology presented updated VERSATILE-002 trial data on Versamune HPV + KEYTRUDA for HPV16+ recurrent/metastatic HNSCC at ESMO 2024. Median Overall Survival was 30 months (95% CI 19.7), compared to 12-18 months for pembrolizumab. Objective Response Rate was 36% vs. 19-25%, Disease Control Rate was 77%, and 21% had deep tumor responses. 9% had complete responses, and 9 patients experienced Grade ≥3 treatment-related adverse events.
Reference News
PDS Biotechnology presented updated VERSATILE-002 trial data on Versamune HPV + KEYTRUDA for HPV16+ recurrent/metastatic HNSCC at ESMO 2024. Median Overall Survival was 30 months (95% CI 19.7), compared to 12-18 months for pembrolizumab. Objective Response Rate was 36% vs. 19-25%, Disease Control Rate was 77%, and 21% had deep tumor responses. 9% had complete responses, and 9 patients experienced Grade ≥3 treatment-related adverse events.